121 related articles for article (PubMed ID: 9859967)
1. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial.
Sheon AR; Wagner L; McElrath MJ; Keefer MC; Zimmerman E; Israel H; Berger D; Fast P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):519-26. PubMed ID: 9859967
[TBL] [Abstract][Full Text] [Related]
2. Trial-related discrimination in HIV vaccine clinical trials.
Allen M; Israel H; Rybczyk K; Pugliese MA; Loughran K; Wagner L; Erb S
AIDS Res Hum Retroviruses; 2001 May; 17(8):667-74. PubMed ID: 11429107
[TBL] [Abstract][Full Text] [Related]
3. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand.
Jenkins RA; Thapinta D; Morgan PA; Wongkamhaeng S; Sornsathapornkul P; Bussaratid V; Sontirat A; Pitisuttithum P; Thongchareoen P; Khamboonruang C; Suriyanon V; Nitayaphan S; Brown AE;
J Acquir Immune Defic Syndr; 2005 Dec; 40(5):592-9. PubMed ID: 16284537
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers.
Thapinta D; Jenkins RA; Celentano DD; Nitayaphan S; Buapunth P; Triampon A; Morgan PA; Khamboonruang C; Suwanarach C; Yutabootr Y; Ruckphaopunt S; Suwankiti S; Tubtong V; Cheewawat W; McNeil JG; Michael RA
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):308-14. PubMed ID: 10077182
[TBL] [Abstract][Full Text] [Related]
5. Negative social impacts among volunteers in an HIV vaccine efficacy trial.
Fuchs J; Durham M; McLellan-Lemal E; Vittinghoff E; Colfax G; Gurwith M; Buchbinder S
J Acquir Immune Defic Syndr; 2007 Nov; 46(3):362-8. PubMed ID: 17721399
[TBL] [Abstract][Full Text] [Related]
6. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
[TBL] [Abstract][Full Text] [Related]
7. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention.
Allen M; Lau CY
Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272
[TBL] [Abstract][Full Text] [Related]
8. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand.
Thapinta D; Jenkins RA
Contemp Clin Trials; 2007 Jul; 28(4):409-22. PubMed ID: 17196444
[TBL] [Abstract][Full Text] [Related]
9. "Once I begin to participate, people will run away from me": understanding stigma as a barrier to HIV vaccine research participation in Kenya.
Nyblade L; Singh S; Ashburn K; Brady L; Olenja J
Vaccine; 2011 Nov; 29(48):8924-8. PubMed ID: 21964057
[TBL] [Abstract][Full Text] [Related]
10. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
[TBL] [Abstract][Full Text] [Related]
11. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.
Newman PA; Daley A; Halpenny R; Loutfy M
Vaccine; 2008 Feb; 26(8):1091-7. PubMed ID: 18237829
[TBL] [Abstract][Full Text] [Related]
12. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand.
Pitisuttithum P; Choopanya K; Bussaratid V; Vanichseni S; van Griensven F; Phonrat B; Martin M; Vimutsunthorn E; Sangkum U; Kitayaporn D; Tappero JW; Heyward W; Francis D
J Med Assoc Thai; 2007 Nov; 90(11):2442-8. PubMed ID: 18181333
[TBL] [Abstract][Full Text] [Related]
13. Social and Behavioral Consequences of Participation in HIV Preventive Vaccine Trials in the ANRS COHVAC Cohort.
Durier C; Desaint C; Launay O
J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S37-S50. PubMed ID: 30222704
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials.
Durier C; Desaint C; Lelièvre JD; Silbermann B; Pialoux G; Cuzin L; Bonnet B; Poizot-Martin I; Bouakane A; Paul C; Grabar S; Spire B; Meyer L; Launay O;
AIDS; 2019 Nov; 33(13):2061-2071. PubMed ID: 31306171
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
[TBL] [Abstract][Full Text] [Related]
16. Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania.
Tarimo EA; Thorson A; Kohi TW; Bakari M; Mhalu F; Kulane A
PLoS One; 2011 Feb; 6(2):e14619. PubMed ID: 21358826
[TBL] [Abstract][Full Text] [Related]
17. Domestic AIDS vaccine trials: addressing the potential for social harm to the subjects of human experiments.
Leider PA
Calif Law Rev; 2000; 88():1185-232. PubMed ID: 11067733
[TBL] [Abstract][Full Text] [Related]
18. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
[TBL] [Abstract][Full Text] [Related]
19. Incentives and disincentives to participate in prophylactic HIV vaccine research.
Jenkins RA; Temoshok LR; Virochsiri K
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):36-42. PubMed ID: 7712233
[TBL] [Abstract][Full Text] [Related]
20. Unique risks to volunteers in HIV vaccine trials.
Frey SE
J Investig Med; 2003 Feb; 51 Suppl 1():S18-20. PubMed ID: 12664950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
